JPWO2021257124A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021257124A5
JPWO2021257124A5 JP2022577590A JP2022577590A JPWO2021257124A5 JP WO2021257124 A5 JPWO2021257124 A5 JP WO2021257124A5 JP 2022577590 A JP2022577590 A JP 2022577590A JP 2022577590 A JP2022577590 A JP 2022577590A JP WO2021257124 A5 JPWO2021257124 A5 JP WO2021257124A5
Authority
JP
Japan
Prior art keywords
weeks
administered
antagonist antibody
subject
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577590A
Other languages
Japanese (ja)
Other versions
JP2023531200A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015084 external-priority patent/WO2021257124A1/en
Publication of JP2023531200A publication Critical patent/JP2023531200A/en
Publication of JPWO2021257124A5 publication Critical patent/JPWO2021257124A5/ja
Pending legal-status Critical Current

Links

Claims (75)

食道扁平上皮癌腫（ＥＳＣＣ）を有する対象又は対象集団を治療するための医薬であって、抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストを含み、抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが同時又は別々に１回又は複数回の投与サイクルで対象又は対象集団に投与され、対象又は対象集団がＥＳＣＣのための最終的化学放射線治療を以前に受けた、医薬。 A medicament for treating a subject or a population of subjects with esophageal squamous cell carcinoma (ESCC), comprising an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist, wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are present at the same time. or separately administered to a subject or population of subjects in one or more administration cycles, wherein the subject or population of subjects has previously undergone definitive chemoradiotherapy for ESCC . ＥＳＣＣを有する対象又は対象集団を治療するための医薬であって、抗ＴＩＧＩＴアンタゴニスト抗体を含み、医薬が同時又は別々に１回又は複数回の投与サイクルでＰＤ－１軸結合アンタゴニストと組み合わせて対象又は対象集団に投与され、対象又は対象集団がＥＳＣＣのための最終的化学放射線治療を以前に受けた、医薬。 A medicament for treating a subject or a population of subjects with ESCC comprising an anti-TIGIT antagonist antibody, wherein the medicament is combined with a PD-1 axis binding antagonist in one or more administration cycles, either simultaneously or separately, for the treatment of a subject or a population of subjects with ESCC. A medicament administered to a subject population, wherein the subject or subject population has previously received definitive chemoradiotherapy for ESCC. ＥＳＣＣを有する対象又は対象集団を治療するための医薬であって、ＰＤ－１軸結合アンタゴニストを含み、医薬が同時又は別々に１回又は複数回の投与サイクルで抗ＴＩＧＩＴアンタゴニスト抗体と組み合わせて対象又は対象集団に投与され、対象又は対象集団がＥＳＣＣのための最終的化学放射線治療を以前に受けた、医薬。 A medicament for treating a subject or a population of subjects with ESCC, comprising a PD-1 axis binding antagonist, wherein the medicament is combined with an anti-TIGIT antagonist antibody in one or more administration cycles, either simultaneously or separately, for treating a subject or a population of subjects with ESCC. A medicament administered to a subject population, wherein the subject or subject population has previously received definitive chemoradiotherapy for ESCC. （ａ）最終的化学放射線治療が、抗ＴＩＧＩＴアンタゴニスト抗体又はＰＤ－１軸結合アンタゴニストの投与の８９日よりも前に完了したか、又は（ｂ）最終的化学放射線治療が、放射線学的疾患進行の証拠なしに、少なくとも２サイクルの白金系化学療法及び放射線療法を含む、請求項１～３のいずれか一項に記載の医薬。 (a) Definitive chemoradiotherapy was completed more than 89 days before administration of the anti-TIGIT antagonist antibody or PD-1 axis binding antagonist ; or (b) Definitive chemoradiotherapy was completed prior to radiological disease progression. A medicament according to any one of claims 1 to 3 , comprising at least two cycles of platinum-based chemotherapy and radiotherapy, without evidence of . １回又は複数回の投与サイクル中に化学療法が対象又は対象集団に投与されない、請求項１～４のいずれか一項に記載の医薬。 A medicament according to any one of claims 1 to 4 , wherein no chemotherapy is administered to the subject or population of subjects during one or more administration cycles. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、３週間ごとに約３０ｍｇ～約１２００ｍｇ、３週間ごとに約３０ｍｇ～約８００ｍｇ、或いは３週間ごとに約６００ｍｇの固定用量で投与されるか、又は（ｂ）ＰＤ－１軸結合アンタゴニストが、３週間ごとに約８０ｍｇ～約１６００ｍｇ、３週間ごとに約８００ｍｇ～約１４００ｍｇ、或いは３週間ごとに約１２００ｍｇの固定用量で投与される、請求項１～５のいずれか一項に記載の医薬。 (a) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 30 mg to about 1200 mg every 3 weeks , about 30 mg to about 800 mg every 3 weeks, or about 600 mg every 3 weeks , or (b) PD - any one of claims 1 to 5, wherein the uniaxial binding antagonist is administered at a fixed dose of about 80 mg to about 1600 mg every 3 weeks, about 800 mg to about 1400 mg every 3 weeks, or about 1200 mg every 3 weeks . The medicine according to item 1. 抗ＴＩＧＩＴアンタゴニスト抗体が、３週間ごとに約６００ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、３週間ごとに約１２００ｍｇの固定用量で投与される、請求項６に記載の医薬。 7. The medicament of claim 6 , wherein the anti-TIGIT antagonist antibody is administered at a fixed dose of about 600 mg every three weeks and the PD-1 axis binding antagonist is administered at a fixed dose of about 1200 mg every three weeks. （ａ）（ｉ）抗ＴＩＧＩＴアンタゴニスト抗体が、２週間ごとに約３００ｍｇ～約８００ｍｇ、２週間ごとに約４００ｍｇ～約５００ｍｇ、或いは２週間ごとに約４２０ｍｇの固定用量で投与され、且つ（ｉｉ）ＰＤ－１軸結合アンタゴニストが、２週間ごとに約２００ｍｇ～約１２００ｍｇ、２週間ごとに約８００ｍｇ～約１０００ｍｇ、或いは２週間ごとに約８４０ｍｇの固定用量で投与されるか、又は（ｂ）（ｉ）抗ＴＩＧＩＴアンタゴニスト抗体が、４週間ごとに約７００ｍｇ～約１０００ｍｇ、４週間ごとに約８００ｍｇ～約９００ｍｇ、或いは４週間ごとに約８４０ｍｇの固定用量で投与され、且つ（ｉｉ）ＰＤ－１軸結合アンタゴニストが、４週間ごとに約４００ｍｇ～約２０００ｍｇ、４週間ごとに約１６００ｍｇ～約１８００ｍｇ、或いは４週間ごとに約１６８０ｍｇの固定用量で投与される、請求項１～５のいずれか一項に記載の医薬。 (a) (i) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 300 mg to about 800 mg every two weeks , about 400 mg to about 500 mg every two weeks, or about 420 mg every two weeks , and (ii) the PD-1 axis binding antagonist is administered at a fixed dose of about 200 mg to about 1200 mg every two weeks, about 800 mg to about 1000 mg every two weeks, or about 840 mg every two weeks, or (b) (i ) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 700 mg to about 1000 mg every 4 weeks, about 800 mg to about 900 mg every 4 weeks, or about 840 mg every 4 weeks; and (ii) PD-1 axis binding. 6. The antagonist is administered at a fixed dose of about 400 mg to about 2000 mg every 4 weeks, about 1600 mg to about 1800 mg every 4 weeks, or about 1680 mg every 4 weeks . medicine . （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、２週間ごとに約４２０ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、２週間ごとに約８４０ｍｇの固定用量で投与されるか、又は（ｂ）抗ＴＩＧＩＴアンタゴニスト抗体が、４週間ごとに約８４０ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、４週間ごとに約１６８０ｍｇの固定用量で投与される、請求項８に記載の医薬。 (a) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 420 mg every two weeks and the PD-1 axis binding antagonist is administered at a fixed dose of about 840 mg every two weeks ; or (b) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 840 mg every two weeks; 9. The medicament of claim 8 , wherein the TIGIT antagonist antibody is administered at a fixed dose of about 840 mg every 4 weeks and the PD-1 axis binding antagonist is administered at a fixed dose of about 1680 mg every 4 weeks . 抗ＴＩＧＩＴアンタゴニスト抗体が、モノクローナル抗体、及び／又はヒト抗体である、請求項１～９のいずれか一項に記載の医薬。 The medicament according to any one of claims 1 to 9, wherein the anti-TIGIT antagonist antibody is a monoclonal antibody and/or a human antibody. 抗ＴＩＧＩＴアンタゴニスト抗体が、完全長抗体である、請求項１～１０のいずれか一項に記載の医薬。 The medicament according to any one of claims 1 to 10, wherein the anti-TIGIT antagonist antibody is a full-length antibody. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、チラゴルマブ、ビボストリマブ、エチギリマブ、又はＥＯＳ０８４４４８である、
（ｂ）抗ＴＩＧＩＴアンタゴニスト抗体が、以下の超可変領域（ＨＶＲ）：
ＳＮＳＡＡＷＮ（配列番号１）のアミノ酸配列を含むＨＶＲ－Ｈ１配列；
ＫＴＹＹＲＦＫＷＹＳＤＹＡＶＳＶＫＧ（配列番号２）のアミノ酸配列を含むＨＶＲ－Ｈ２配列；
ＥＳＴＴＹＤＬＬＡＧＰＦＤＹ（配列番号３）のアミノ酸配列を含むＨＶＲ－Ｈ３配列；
ＫＳＳＱＴＶＬＹＳＳＮＮＫＫＹＬＡ（配列番号４）のアミノ酸配列を含むＨＶＲ－Ｌ１配列；
ＷＡＳＴＲＥＳ（配列番号５）のアミノ酸配列を含むＨＶＲ－Ｌ２配列；及び
ＱＱＹＹＳＴＰＦＴ（配列番号６）のアミノ酸配列を含むＨＶＲ－Ｌ３配列
を含む、並びに／又は
（ｃ）抗ＴＩＧＩＴアンタゴニスト抗体が、配列番号１７又は１８のアミノ酸配列を含むＶＨドメイン、及び配列番号１９のアミノ酸配列を含むＶＬドメインを含む、請求項１～１１のいずれか一項に記載の医薬。 (a) the anti-TIGIT antagonist antibody is tiragolumab, vivostrimab, etigilimab, or EOS084448;
(b) The anti-TIGIT antagonist antibody has the following hypervariable region (HVR):
HVR-H1 sequence comprising the amino acid sequence of SNSAAWN (SEQ ID NO: 1);
HVR-H2 sequence comprising the amino acid sequence of KTYYRFKWYSDYAVSVKG (SEQ ID NO: 2);
HVR-H3 sequence comprising the amino acid sequence of ESTTYDLLAGPFDY (SEQ ID NO: 3);
HVR-L1 sequence comprising the amino acid sequence of KSSQTVLYSSNNKKYLA (SEQ ID NO: 4);
HVR-L2 sequence comprising the amino acid sequence of WASTRES (SEQ ID NO: 5); and HVR-L3 sequence comprising the amino acid sequence of QQYYSTPFT (SEQ ID NO: 6) , and/or
(c) The medicament according to any one of claims 1 to 11, wherein the anti-TIGIT antagonist antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 17 or 18, and a VL domain comprising the amino acid sequence of SEQ ID NO: 19. . 抗ＴＩＧＩＴアンタゴニスト抗体が、チラゴルマブである、請求項１～１２のいずれか一項に記載の医薬。 The medicament according to any one of claims 1 to 12 , wherein the anti-TIGIT antagonist antibody is tiragolumab. 抗ＴＩＧＩＴアンタゴニスト抗体が、Ｆａｂ、Ｆａｂ’、Ｆａｂ’－ＳＨ、Ｆｖ、一本鎖可変フラグメント（ｓｃＦｖ）、及び（Ｆａｂ’）２フラグメントからなる群から選択されるＴＩＧＩＴに結合する抗体フラグメントである、請求項１～１０のいずれか一項に記載の医薬。 the anti-TIGIT antagonist antibody is an antibody fragment that binds TIGIT selected from the group consisting of Fab, Fab', Fab'-SH, Fv, single chain variable fragment (scFv), and (Fab') 2 fragment; The medicament according to any one of claims 1 to 10 . ＰＤ－１軸結合アンタゴニストが、ＰＤ－Ｌ１結合アンタゴニスト又はＰＤ－１結合アンタゴニストである、請求項１～１４のいずれか一項に記載の医薬。 The medicament according to any one of claims 1 to 14 , wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist or a PD-1 binding antagonist. ＰＤ－Ｌ１結合アンタゴニストが、抗ＰＤ－Ｌ１アンタゴニスト抗体である、請求項１５に記載の医薬。 The medicament according to claim 15 , wherein the PD-L1 binding antagonist is an anti-PD-L1 antagonist antibody. （ａ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、アテゾリズマブ、ＭＳＢ００１０７１８Ｃ、ＭＤＸ－１１０５又はＭＥＤＩ４７３６である、
（ｂ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、以下のＨＶＲ：
ＧＦＴＦＳＤＳＷＩＨ（配列番号２０）のアミノ酸配列を含むＨＶＲ－Ｈ１配列；
ＡＷＩＳＰＹＧＧＳＴＹＹＡＤＳＶＫＧ（配列番号２１）のアミノ酸配列を含むＨＶＲ－Ｈ２配列；
ＲＨＷＰＧＧＦＤＹ（配列番号２２）のアミノ酸配列を含むＨＶＲ－Ｈ３配列；
ＲＡＳＱＤＶＳＴＡＶＡ（配列番号２３）のアミノ酸配列を含むＨＶＲ－Ｌ１配列；
ＳＡＳＦＬＹＳ（配列番号２４）のアミノ酸配列を含むＨＶＲ－Ｌ２配列；及び
ＱＱＹＬＹＨＰＡＴ（配列番号２５）のアミノ酸配列を含むＨＶＲ－Ｌ３配列
を含む、並びに／又は
（ｃ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、配列番号２６のアミノ酸配列を含むＶＨドメイン、及び配列番号２７のアミノ酸配列を含むＶＬドメインを含む、請求項１～１６のいずれか一項に記載の医薬。 (a) the anti-PD-L1 antagonist antibody is atezolizumab, MSB0010718C, MDX-1105 or MEDI4736;
(b) The anti-PD-L1 antagonist antibody has the following HVR:
HVR-H1 sequence comprising the amino acid sequence of GFTFSDSWIH (SEQ ID NO: 20);
HVR-H2 sequence comprising the amino acid sequence of AWISPYGGSTYYADSVKG (SEQ ID NO: 21);
HVR-H3 sequence comprising the amino acid sequence of RHWPGGFDY (SEQ ID NO: 22);
HVR-L1 sequence comprising the amino acid sequence of RASQDVSTAVA (SEQ ID NO: 23);
an HVR-L2 sequence comprising the amino acid sequence of SASFLYS (SEQ ID NO: 24); and
HVR-L3 sequence containing the amino acid sequence of QQYLYHPAT (SEQ ID NO: 25)
including and/or
(c) The medicament according to any one of claims 1 to 16 , wherein the anti-PD-L1 antagonist antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 26 and a VL domain comprising the amino acid sequence of SEQ ID NO: 27. . 抗ＰＤ－Ｌ１アンタゴニスト抗体が、アテゾリズマブである、請求項１７に記載の医薬。 18. The medicament according to claim 17 , wherein the anti-PD-L1 antagonist antibody is atezolizumab. ＰＤ－１結合アンタゴニストが、抗ＰＤ－１アンタゴニスト抗体である、請求項１５に記載の医薬。 The medicament according to claim 15 , wherein the PD-1 binding antagonist is an anti-PD-1 antagonist antibody. １回又は複数回の投与サイクルのそれぞれの約１日目に、抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが対象又は対象集団に投与される、請求項１～１９のいずれか一項に記載の医薬。 20. The anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are administered to the subject or population of subjects on about day 1 of each of the one or more administration cycles. medicine . （ａ）抗ＴＩＧＩＴアンタゴニスト抗体の前に、ＰＤ－１軸結合アンタゴニストが対象又は対象集団に投与される、（ｂ）ＰＤ－１軸結合アンタゴニストの前に、抗ＴＩＧＩＴアンタゴニスト抗体が対象又は対象集団に投与される、又は（ｃ）抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが対象又は対象集団に同時に投与される、請求項１～２０のいずれか一項に記載の医薬。 (a) the PD-1 axis binding antagonist is administered to the subject or subject population before the anti-TIGIT antagonist antibody; (b) the anti-TIGIT antagonist antibody is administered to the subject or subject population before the PD-1 axis binding antagonist. or (c) the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are administered simultaneously to a subject or a population of subjects . 対象又は対象集団から得られたＥＳＣＣ腫瘍試料が、検出可能なＰＤ－Ｌ１発現レベルを有すると決定されている、請求項１～２１のいずれか一項に記載の医薬。 22. A medicament according to any one of claims 1 to 21 , wherein the ESCC tumor sample obtained from the subject or population of subjects has been determined to have a detectable level of PD-L1 expression. 検出可能なＰＤ－Ｌ１発現レベルが、検出可能なＰＤ－Ｌ１タンパク質発現レベル、又は検出可能なＰＤ－Ｌ１核酸発現レベルである、請求項２２に記載の医薬。 23. The medicament according to claim 22 , wherein the detectable PD-L1 expression level is a detectable PD-L1 protein expression level or a detectable PD-L1 nucleic acid expression level . ＥＳＣＣが、局所進行性ＥＳＣＣ、切除不能ＥＳＣＣ、再発性又は転移性ＥＳＣＣ、又は頸部食道腫瘍である、請求項１～２２のいずれか一項に記載の医薬。 23. The medicament according to any one of claims 1 to 22 , wherein the ESCC is locally advanced ESCC , unresectable ESCC, recurrent or metastatic ESCC, or cervical esophageal tumor . ＥＳＣＣが、ステージＩＩ ＥＳＣＣ、ステージＩＩＩ ＥＳＣＣ又はステージＩＶ ＥＳＣＣであり、任意に、ステージＩＶ ＥＳＣＣが、鎖骨上リンパ節転移のみを伴うステージＩＶＡ ＥＳＣＣ又はステージＩＶＢ ＥＳＣＣである、請求項１～２４のいずれか一項に記載の医薬。 25. Any of claims 1-24 , wherein the ESCC is Stage II ESCC, Stage III ESCC or Stage IV ESCC, optionally the Stage IV ESCC is Stage IVA ESCC or Stage IVB ESCC with only supraclavicular lymph node metastases. The medicine described in item (1) above. （ａ）対象又は対象集団が、以前にがん免疫療法で治療されたことがない、又は（ｂ）対象又は対象集団が、ＥＳＣＣのための以前のがん免疫療法を完了している、請求項１～２５のいずれか一項に記載の医薬。 The claim is that (a) the subject or population has not been previously treated with cancer immunotherapy, or (b) the subject or population has completed previous cancer immunotherapy for ESCC. Item 26. The medicament according to any one of Items 1 to 25 . 治療が、（ｉ）抗ＴＩＧＩＴアンタゴニスト抗体を用いずにＰＤ－１軸結合アンタゴニストを用いた治療、（ｉｉ）ＰＤ－１軸結合アンタゴニストを用いずに抗ＴＩＧＩＴアンタゴニスト抗体を用いた治療、又は（ｉｉｉ）抗ＴＩＧＩＴアンタゴニスト抗体を用いず、かつ、ＰＤ－１軸結合アンタゴニストを用いない治療と比較して、対象又は対象集団の無増悪生存期間（ＰＦＳ）、全生存期間（ＯＳ）、及び／又は客観的奏効期間（ＤＯＲ）の増加をもたらす、請求項１～２６のいずれか一項に記載の医薬。 The treatment is (i) treatment with a PD-1 axis binding antagonist without an anti-TIGIT antagonist antibody , (ii) treatment with an anti-TIGIT antagonist antibody without a PD-1 axis binding antagonist, or (iii) ) Progression-free survival (PFS) , overall survival (OS), and/or objective of a subject or subject population compared to treatment without an anti-TIGIT antagonist antibody and without a PD-1 axis binding antagonist 27. A medicament according to any one of claims 1 to 26 , which results in an increase in duration of response (DOR) . 治療が、完全奏効又は部分奏効をもたらす、請求項１～２７のいずれか一項に記載の医薬。 28. The medicament according to any one of claims 1 to 27 , wherein the treatment results in a complete response or a partial response. 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが、対象又は対象集団に少なくとも５回の投与サイクルで投与される、請求項１～２８のいずれか一項に記載の医薬。 29. A medicament according to any one of claims 1 to 28 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are administered to the subject or population of subjects in at least 5 administration cycles. 請求項１～２９のいずれか一項に記載の医薬の製造における抗ＴＩＧＩＴアンタゴニスト抗体の使用。 Use of an anti-TIGIT antagonist antibody in the manufacture of a medicament according to any one of claims 1 to 29 . 請求項１～２９のいずれか一項に記載の医薬の製造におけるＰＤ－１軸結合アンタゴニストの使用。 Use of a PD-1 axis binding antagonist in the manufacture of a medicament according to any one of claims 1 to 29 . 請求項１～２９のいずれか一項に記載の医薬の製造における抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストの使用。 Use of an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist in the manufacture of a medicament according to any one of claims 1 to 29. 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが別々に製剤化される、請求項３０～３２のいずれか一項に記載の使用。 33. The use according to any one of claims 30 to 32 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are formulated separately. 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが一緒に製剤化される、請求項３０～３２のいずれか一項に記載の使用。 33. The use according to any one of claims 30 to 32 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are formulated together. 手術が不適切である進行性のＥＳＣＣを有する対象又は対象集団を治療するための医薬であって、抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストを含み、医薬が、タキサン及び白金薬剤と組み合わせて同時又は別々に１回又は複数回の投与サイクルで対象又は対象集団に投与される、医薬。 A medicament for treating a subject or population of subjects with advanced ESCC for whom surgery is inappropriate, the medicament comprising an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist, the medicament comprising a taxane and a platinum drug. A medicament that is administered in combination, simultaneously or separately, to a subject or a population of subjects in one or more administration cycles. 手術が不適切である進行性のＥＳＣＣを有する対象又は対象集団を治療するための医薬であって、抗ＴＩＧＩＴアンタゴニスト抗体を含み、医薬が、ＰＤ－１軸結合アンタゴニスト、タキサン及び白金薬剤と組み合わせて同時又は別々に１回又は複数回の投与サイクルで対象又は対象集団に投与される、医薬。 A medicament for treating a subject or population of subjects with advanced ESCC for whom surgery is inappropriate, the medicament comprising an anti-TIGIT antagonist antibody, wherein the medicament is in combination with a PD-1 axis binding antagonist, a taxane, and a platinum drug. A medicament that is administered to a subject or a population of subjects in one or more administration cycles, either simultaneously or separately. 手術が不適切である進行性のＥＳＣＣを有する対象又は対象集団を治療するための医薬であって、ＰＤ－１軸結合アンタゴニストを含み、医薬が、抗ＴＩＧＩＴアンタゴニスト抗体、タキサン及び白金薬剤と組み合わせて同時又は別々に１回又は複数回の投与サイクルで対象又は対象集団に投与される、医薬。 A medicament for treating a subject or population of subjects with advanced ESCC for whom surgery is inappropriate, the medicament comprising a PD-1 axis binding antagonist, the medicament in combination with an anti-TIGIT antagonist antibody, a taxane, and a platinum drug. A medicament that is administered to a subject or a population of subjects in one or more administration cycles, either simultaneously or separately. 対象又は対象集団が、（ａ）進行性のＥＳＣＣのための以前の全身治療を受けたことがない、（ｂ）非進行性のＥＳＣＣのための以前の全身治療を受けたことがない、（ｃ）非進行性のＥＳＣＣのための以前の治療を受けたことがあり、非進行性のＥＳＣＣのための以前の治療が、進行性のＥＳＣＣの診断の少なくとも６ヶ月前に完了した、請求項３５～３７のいずれか一項に記載の医薬。 The subject or target population (a) has not received prior systemic treatment for advanced ESCC ; (b) has not received prior systemic treatment for non-progressive ESCC; c) have received prior treatment for non-progressive ESCC, and the prior treatment for non-progressive ESCC was completed at least 6 months prior to the diagnosis of progressive ESCC; 38. The medicament according to any one of 35 to 37 . 非進行性のＥＳＣＣのための以前の治療が、化学放射線療法又は化学療法を含む、請求項３８に記載の医薬。 39. A medicament according to claim 38 , wherein previous treatment for non-progressive ESCC comprises chemoradiotherapy or chemotherapy. 化学放射線療法又は化学療法が、治癒目的で、又はアジュバント若しくはネオアジュバント状況において投与された、請求項３９に記載の医薬。 40. A medicament according to claim 39 , wherein the chemoradiotherapy or chemotherapy is administered with curative intent or in an adjuvant or neoadjuvant setting. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、３週間ごとに約３０ｍｇ～約１２００ｍｇ、３週間ごとに約３０ｍｇ～約８００ｍｇ、或いは３週間ごとに約６００ｍｇの固定用量で投与されるか、又は
（ｂ）ＰＤ－１軸結合アンタゴニストが、３週間ごとに約８０ｍｇ～約１６００ｍｇ、３週間ごとに約８００ｍｇ～約１４００ｍｇ、３週間ごとに約１２００ｍｇの固定用量で投与される、請求項３５～４０のいずれか一項に記載の医薬。 (a) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 30 mg to about 1200 mg every 3 weeks , about 30 mg to about 800 mg every 3 weeks, or about 600 mg every 3 weeks , or
(b) the PD-1 axis binding antagonist is administered at a fixed dose of about 80 mg to about 1600 mg every 3 weeks, about 800 mg to about 1400 mg every 3 weeks, about 1200 mg every 3 weeks , The medicament according to any one of . （ａ）タキサンが、（ｉ）３週間ごとに約１００～２５０ｍｇ／ｍ２ 、（ｉｉ）３週間ごとに１５０～２００ｍｇ／ｍ ２ 、或いは（ｉｉｉ）３週間ごとに１７５ｍｇ／ｍ ２ の用量で投与されるか、又は
（ｂ）白金薬剤が、（ｉ）３週間ごとに約２０～２００ｍｇ／ｍ ２ 、（ｉｉ）３週間ごとに約４０～１２０ｍｇ／ｍ ２ 、或いは（ｉｉｉ）３週間ごとに約６０～８０ｍｇ／ｍ ２ の用量で投与される、請求項３５～４１のいずれか一項に記載の医薬。 (a) the taxane is administered at a dose of (i) about 100-250 mg/m 2 every 3 weeks , (ii) 150-200 mg/m 2 every 3 weeks, or (iii) 175 mg/m 2 every 3 weeks; administered or
(b) the platinum drug is administered at a dose of (i) about 20-200 mg/m 2 every 3 weeks , (ii) about 40-120 mg/m 2 every 3 weeks , or (iii) about 60-80 mg/m 2 every 3 weeks; 42. A medicament according to any one of claims 35 to 41 , administered in a dose of m2 . 抗ＴＩＧＩＴアンタゴニスト抗体が、３週間ごとに約６００ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、３週間ごとに約１２００ｍｇの固定用量で投与され、タキサンが、３週間ごとに約１７５ｍｇ／ｍ２の用量で投与され、白金薬剤が、３週間ごとに約６０～８０ｍｇ／ｍ２の用量で投与される、請求項４２に記載の医薬。 The anti-TIGIT antagonist antibody is administered at a fixed dose of about 600 mg every 3 weeks, the PD-1 axis binding antagonist is administered at a fixed dose of about 1200 mg every 3 weeks, and the taxane is administered at a fixed dose of about 175 mg every 3 weeks. 43. A medicament according to claim 42 , wherein the platinum drug is administered at a dose of about 60-80 mg/ m2 every three weeks. 抗ＴＩＧＩＴアンタゴニスト抗体、ＰＤ－１軸結合アンタゴニスト、タキサン、及び白金薬剤が、４～８回の導入期の投与サイクルの各々で投与される、請求項３５～４３のいずれか一項に記載の医薬。 44. A medicament according to any one of claims 35 to 43 , wherein the anti-TIGIT antagonist antibody, the PD-1 axis binding antagonist, the taxane, and the platinum drug are administered in each of 4 to 8 induction phase administration cycles. . 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが、導入期の投与サイクルに続いて１回又は複数回の維持期の投与サイクルで更に投与される、請求項４４に記載の医薬。 45. The medicament of claim 44, wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are further administered in one or more maintenance administration cycles following the induction administration cycle. タキサン及び白金薬剤が、１回又は複数回の維持期の投与サイクルの各々から省略される、請求項４５に記載の医薬。 46. The medicament of claim 45 , wherein the taxane and platinum drug are omitted from each of the one or more maintenance phase administration cycles. （ａ）（ｉ）抗ＴＩＧＩＴアンタゴニスト抗体が、２週間ごとに約３００ｍｇ～約８００ｍｇ、２週間ごとに約４００ｍｇ～約５００ｍｇ、或いは２週間ごとに約４２０ｍｇの固定用量で投与され、且つ（ｉｉ）ＰＤ－１軸結合アンタゴニストが、２週間ごとに約２００ｍｇ～約１２００ｍｇ、２週間ごとに約８００ｍｇ～約１０００ｍｇ、或いは２週間ごとに約８４０ｍｇの固定用量で投与されるか、又は
（ｂ）（ｉ）抗ＴＩＧＩＴアンタゴニスト抗体が、４週間ごとに約７００ｍｇ～約１０００ｍｇ、４週間ごとに約８００ｍｇ～約９００ｍｇ、或いは４週間ごとに約８４０ｍｇの固定用量で投与され、且つ（ｉｉ）ＰＤ－１軸結合アンタゴニストが、４週間ごとに約４００ｍｇ～約２０００ｍｇ、４週間ごとに約１６００ｍｇ～約１８００ｍｇ、或いは４週間ごとに約１６８０ｍｇの固定用量で投与される、請求項３５～４０のいずれか一項に記載の医薬。 (a) (i) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 300 mg to about 800 mg every two weeks , about 400 mg to about 500 mg every two weeks, or about 420 mg every two weeks , and (ii) the PD-1 axis binding antagonist is administered at a fixed dose of about 200 mg to about 1200 mg every two weeks, about 800 mg to about 1000 mg every two weeks, or about 840 mg every two weeks, or
(b) (i) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 700 mg to about 1000 mg every 4 weeks, about 800 mg to about 900 mg every 4 weeks, or about 840 mg every 4 weeks, and (ii) Any of claims 35-40 , wherein the PD-1 axis binding antagonist is administered at a fixed dose of about 400 mg to about 2000 mg every 4 weeks, about 1600 mg to about 1800 mg every 4 weeks, or about 1680 mg every 4 weeks . The medicine described in item (1) above. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、２週間ごとに約４２０ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、２週間ごとに約８４０ｍｇの固定用量で投与されるか、又は
（ｂ）抗ＴＩＧＩＴアンタゴニスト抗体が、４週間ごとに約８４０ｍｇの固定用量で投与され、ＰＤ－１軸結合アンタゴニストが、４週間ごとに約１６８０ｍｇの固定用量で投与される、請求項４７に記載の医薬。 (a) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 420 mg every two weeks and the PD-1 axis binding antagonist is administered at a fixed dose of about 840 mg every two weeks , or
(b) the anti-TIGIT antagonist antibody is administered at a fixed dose of about 840 mg every 4 weeks and the PD-1 axis binding antagonist is administered at a fixed dose of about 1680 mg every 4 weeks . Medicine . 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが、１回又は複数回の維持期の投与サイクルで更に投与され、タキサン及び白金薬剤が、１回又は複数回の維持期の投与サイクルの各々から省略される、請求項４７又は４８に記載の医薬。 The anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are further administered in one or more maintenance phase administration cycles, and the taxane and platinum drug are omitted from each of the one or more maintenance phase administration cycles. 49. The medicament according to claim 47 or 48 . （ａ）タキサンが、１週間ごとに１回、２週間ごとに１回、３週間ごとに１回、３週間ごとに２回、４週間ごとに１回、４週間ごとに２回、又は４週間ごとに３回投与されるか、又は（ｂ）白金薬剤が、１週間ごとに１回、２週間ごとに１回、３週間ごとに１回、３週間ごとに２回、４週間ごとに１回、４週間ごとに２回、又は４週間ごとに３回投与される、請求項４７～４９のいずれか一項に記載の医薬。 (a) the taxane is administered once every week, once every two weeks, once every three weeks, twice every three weeks, once every four weeks, twice every four weeks, or or (b) the platinum drug is administered once every week, once every two weeks, once every three weeks, twice every three weeks, or (b) the platinum drug is administered three times every three weeks, or (b) the platinum drug is administered once every week, once every two weeks, once every three weeks, twice every three weeks, or every four weeks. 50. A medicament according to any one of claims 47 to 49 , which is administered once, twice every four weeks, or three times every four weeks . 抗ＴＩＧＩＴアンタゴニスト抗体が、モノクローナル抗体、及び／又はヒト抗体である、請求項３５～５０のいずれか一項に記載の医薬。 The medicament according to any one of claims 35 to 50, wherein the anti-TIGIT antagonist antibody is a monoclonal antibody and/or a human antibody. 抗ＴＩＧＩＴアンタゴニスト抗体が、完全長抗体である、請求項３５～５１のいずれか一項に記載の医薬。 52. The medicament according to any one of claims 35 to 51, wherein the anti-TIGIT antagonist antibody is a full-length antibody. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体が、以下の超可変領域（ＨＶＲ）：
ＳＮＳＡＡＷＮ（配列番号１）のアミノ酸配列を含むＨＶＲ－Ｈ１配列；
ＫＴＹＹＲＦＫＷＹＳＤＹＡＶＳＶＫＧ（配列番号２）のアミノ酸配列を含むＨＶＲ－Ｈ２配列；
ＥＳＴＴＹＤＬＬＡＧＰＦＤＹ（配列番号３）のアミノ酸配列を含むＨＶＲ－Ｈ３配列；
ＫＳＳＱＴＶＬＹＳＳＮＮＫＫＹＬＡ（配列番号４）のアミノ酸配列を含むＨＶＲ－Ｌ１配列；
ＷＡＳＴＲＥＳ（配列番号５）のアミノ酸配列を含むＨＶＲ－Ｌ２配列；及び
ＱＱＹＹＳＴＰＦＴ（配列番号６）のアミノ酸配列を含むＨＶＲ－Ｌ３配列
を含む、並びに／又は
（ｃ）抗ＴＩＧＩＴアンタゴニスト抗体が、配列番号１７又は１８のアミノ酸配列を含むＶＨドメイン、及び配列番号１９のアミノ酸配列を含むＶＬドメインを含む、請求項３５～５２のいずれか一項に記載の医薬。 (a) The anti-TIGIT antagonist antibody has the following hypervariable region (HVR):
HVR-H1 sequence comprising the amino acid sequence of SNSAAWN (SEQ ID NO: 1);
HVR-H2 sequence comprising the amino acid sequence of KTYYRFKWYSDYAVSVKG (SEQ ID NO: 2);
HVR-H3 sequence comprising the amino acid sequence of ESTTYDLLAGPFDY (SEQ ID NO: 3);
HVR-L1 sequence comprising the amino acid sequence of KSSQTVLYSSNNKKYLA (SEQ ID NO: 4);
HVR-L2 sequence comprising the amino acid sequence of WASTRES (SEQ ID NO: 5); and HVR-L3 sequence comprising the amino acid sequence of QQYYSTPFT (SEQ ID NO: 6) , and/or
(c) The medicament according to any one of claims 35 to 52, wherein the anti-TIGIT antagonist antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 17 or 18 and a VL domain comprising the amino acid sequence of SEQ ID NO: 19. . 抗ＴＩＧＩＴアンタゴニスト抗体が、チラゴルマブである、請求項３５～５３のいずれか一項に記載の医薬。 54. The medicament according to any one of claims 35 to 53 , wherein the anti-TIGIT antagonist antibody is tiragolumab. 抗ＴＩＧＩＴアンタゴニスト抗体が、Ｆａｂ、Ｆａｂ’、Ｆａｂ’－ＳＨ、Ｆｖ、一本鎖可変フラグメント（ｓｃＦｖ）、及び（Ｆａｂ’）２フラグメントからなる群から選択されるＴＩＧＩＴに結合する抗体フラグメントである、請求項３５～５１のいずれか一項に記載の医薬。 the anti-TIGIT antagonist antibody is an antibody fragment that binds TIGIT selected from the group consisting of Fab, Fab', Fab'-SH, Fv, single chain variable fragment (scFv), and (Fab') 2 fragment; The medicament according to any one of claims 35 to 51 . ＰＤ－１軸結合アンタゴニストが、ＰＤ－Ｌ１結合アンタゴニスト又はＰＤ－１結合アンタゴニストである、請求項３５～５５のいずれか一項に記載の医薬。 The medicament according to any one of claims 35 to 55 , wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist or a PD-1 binding antagonist. ＰＤ－Ｌ１結合アンタゴニストが、抗ＰＤ－Ｌ１アンタゴニスト抗体である、請求項５６に記載の医薬。 57. The medicament according to claim 56 , wherein the PD-L1 binding antagonist is an anti-PD-L1 antagonist antibody. （ａ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、アテゾリズマブ、ＭＳＢ００１０７１８Ｃ、ＭＤＸ－１１０５又はＭＥＤＩ４７３６である、
（ｂ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、以下のＨＶＲ：
ＧＦＴＦＳＤＳＷＩＨ（配列番号２０）のアミノ酸配列を含むＨＶＲ－Ｈ１配列；
ＡＷＩＳＰＹＧＧＳＴＹＹＡＤＳＶＫＧ（配列番号２１）のアミノ酸配列を含むＨＶＲ－Ｈ２配列；
ＲＨＷＰＧＧＦＤＹ（配列番号２２）のアミノ酸配列を含むＨＶＲ－Ｈ３配列；
ＲＡＳＱＤＶＳＴＡＶＡ（配列番号２３）のアミノ酸配列を含むＨＶＲ－Ｌ１配列；
ＳＡＳＦＬＹＳ（配列番号２４）のアミノ酸配列を含むＨＶＲ－Ｌ２配列；及び
ＱＱＹＬＹＨＰＡＴ（配列番号２５）のアミノ酸配列を含むＨＶＲ－Ｌ３配列
を含む、並びに／又は
（ｃ）抗ＰＤ－Ｌ１アンタゴニスト抗体が、配列番号２６のアミノ酸配列を含むＶＨドメイン、及び配列番号２７のアミノ酸配列を含むＶＬドメインを含む、請求項３５～５７のいずれか一項に記載の医薬。 (a) the anti-PD-L1 antagonist antibody is atezolizumab, MSB0010718C, MDX-1105 or MEDI4736 ;
(b) The anti-PD-L1 antagonist antibody has the following HVR:
HVR-H1 sequence comprising the amino acid sequence of GFTFSDSWIH (SEQ ID NO: 20);
HVR-H2 sequence comprising the amino acid sequence of AWISPYGGSTYYADSVKG (SEQ ID NO: 21);
HVR-H3 sequence comprising the amino acid sequence of RHWPGGFDY (SEQ ID NO: 22);
HVR-L1 sequence comprising the amino acid sequence of RASQDVSTAVA (SEQ ID NO: 23);
an HVR-L2 sequence comprising the amino acid sequence of SASFLYS (SEQ ID NO: 24); and
HVR-L3 sequence containing the amino acid sequence of QQYLYHPAT (SEQ ID NO: 25)
including and/or
(c) The medicament according to any one of claims 35 to 57, wherein the anti-PD-L1 antagonist antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 26 and a VL domain comprising the amino acid sequence of SEQ ID NO: 27. . 抗ＰＤ－Ｌ１アンタゴニスト抗体が、アテゾリズマブである、請求項５８に記載の医薬。 59. The medicament according to claim 58 , wherein the anti-PD-L1 antagonist antibody is atezolizumab. ＰＤ－１結合アンタゴニストが、抗ＰＤ－１アンタゴニスト抗体である、請求項５６に記載の医薬。 57. The medicament according to claim 56 , wherein the PD-1 binding antagonist is an anti-PD-1 antagonist antibody. タキサンが、パクリタキセル又はｎａｂ－パクリタキセルである、請求項３５～６０のいずれか一項に記載の医薬。 The medicament according to any one of claims 35 to 60 , wherein the taxane is paclitaxel or nab-paclitaxel. 白金薬剤が、シスプラチン又はカルボプラチンである、請求項３５～６１のいずれか一項に記載の医薬。 62. The medicament according to any one of claims 35 to 61 , wherein the platinum drug is cisplatin or carboplatin. （ａ）抗ＴＩＧＩＴアンタゴニスト抗体の前に、ＰＤ－１軸結合アンタゴニストを対象又は対象集団に投与される、（ｂ）ＰＤ－１軸結合アンタゴニストの前に、抗ＴＩＧＩＴアンタゴニスト抗体が対象又は対象集団に投与される、又は（ｃ）抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが対象又は対象集団に同時に投与される、請求項３５～６２のいずれか一項に記載の医薬。 (a) the PD-1 axis binding antagonist is administered to the subject or subject population before the anti-TIGIT antagonist antibody ; (b) the anti-TIGIT antagonist antibody is administered to the subject or subject population before the PD-1 axis binding antagonist. 63. The medicament according to any one of claims 35 to 62 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are administered simultaneously to a subject or a population of subjects . タキサン及び／又は白金薬剤の前に、抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが投与される、請求項３５～６３のいずれか一項に記載の医薬。 64. The medicament according to any one of claims 35 to 63 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are administered before the taxane and/or platinum drug. 白金薬剤の前に、タキサンが対象又は対象集団に投与される、請求項６４に記載の医薬。 65. The medicament of claim 64 , wherein the taxane is administered to the subject or population of subjects before the platinum drug. 対象又は対象集団から得られたＥＳＣＣ腫瘍試料が、検出可能なＰＤ－Ｌ１発現レベルを有すると決定されている、請求項３５～６５のいずれか一項に記載の医薬。 66. A medicament according to any one of claims 35 to 65 , wherein the ESCC tumor sample obtained from the subject or population of subjects has been determined to have a detectable level of PD-L1 expression. 検出可能なＰＤ－Ｌ１発現レベルが、検出可能なＰＤ－Ｌ１タンパク質発現レベルであるル、又は検出可能なＰＤ－Ｌ１核酸発現レベルである、請求項６６に記載の医薬。 67. The medicament according to claim 66 , wherein the detectable PD-L1 expression level is a detectable PD-L1 protein expression level or a detectable PD-L1 nucleic acid expression level . 進行性のＥＳＣＣが、局所進行性ＥＳＣＣ、再発性又は転移性ＥＳＣＣ、又は切除不能ＥＳＣＣである、請求項３５～６７のいずれか一項に記載の医薬。 68. The medicament according to any one of claims 35 to 67 , wherein the advanced ESCC is locally advanced ESCC , recurrent or metastatic ESCC, or unresectable ESCC . 治療が、
（ａ）ＰＤ－１軸結合アンタゴニスト及び抗ＴＩＧＩＴアンタゴニスト抗体を用いずにタキサン及び白金薬剤を用いた治療と比較して、対象又は対象集団のＰＦＳ、ＯＳ、及び／又はＤＯＲの増加、
（ｂ）ＰＤ－１軸結合アンタゴニスト及び抗ＴＩＧＩＴアンタゴニスト抗体を用いずにタキサン及び白金薬剤を用いた治療と比較して、対象又は対象集団のＯＳの増加、又は
（ｃ）ＰＤ－１軸結合アンタゴニスト及び抗ＴＩＧＩＴアンタゴニスト抗体を用いずにタキサン及び白金薬剤を用いた治療と比較して、対象又は対象集団のＤＯＲの増加
をもたらす、請求項３５～６８のいずれか一項に記載の医薬。 The treatment is
(a) an increase in PFS , OS, and/or DOR in a subject or population of subjects as compared to treatment with a taxane and platinum drug without a PD-1 axis binding antagonist and an anti-TIGIT antagonist antibody ;
(b) an increase in the OS of the subject or subject population compared to treatment with a taxane and platinum drug without a PD-1 axis binding antagonist and an anti-TIGIT antagonist antibody, or
(c) increased DOR in a subject or population compared to treatment with a taxane and platinum drug without a PD-1 axis binding antagonist and an anti-TIGIT antagonist antibody;
69. A medicament according to any one of claims 35 to 68 , which provides: 治療が、完全奏効又は部分奏効をもたらす、請求項３５～６９のいずれか一項に記載の医薬。 70. A medicament according to any one of claims 35 to 69 , wherein the treatment results in a complete response or a partial response. 請求項３５～７０のいずれか一項に記載の医薬の製造における抗ＴＩＧＩＴアンタゴニスト抗体の使用。 Use of an anti-TIGIT antagonist antibody in the manufacture of a medicament according to any one of claims 35 to 70 . 請求項３５～７０のいずれか一項に記載の医薬の製造におけるＰＤ－１軸結合アンタゴニストの使用。 Use of a PD-1 axis binding antagonist in the manufacture of a medicament according to any one of claims 35 to 70 . 請求項３５～７０のいずれか一項に記載の医薬の製造における抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストの使用。 Use of an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist in the manufacture of a medicament according to any one of claims 35 to 70. 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが別々に製剤化される、請求項７１～７３のいずれか一項に記載の使用。 74. The use according to any one of claims 71 to 73 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are formulated separately. 抗ＴＩＧＩＴアンタゴニスト抗体及びＰＤ－１軸結合アンタゴニストが一緒に製剤化される、請求項７１～７３のいずれか一項に記載の使用。 74. The use according to any one of claims 71 to 73 , wherein the anti-TIGIT antagonist antibody and the PD-1 axis binding antagonist are formulated together.
JP2022577590A 2020-06-18 2021-01-26 Treatment with anti-TIGIT antibody and PD-1 axis binding antagonist Pending JP2023531200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/096746 2020-06-18
CN2020096746 2020-06-18
PCT/US2021/015084 WO2021257124A1 (en) 2020-06-18 2021-01-26 Treatment with anti-tigit antibodies and pd-1 axis binding antagonists

Publications (2)

Publication Number Publication Date
JP2023531200A JP2023531200A (en) 2023-07-21
JPWO2021257124A5 true JPWO2021257124A5 (en) 2024-02-05

Family

ID=74661506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577590A Pending JP2023531200A (en) 2020-06-18 2021-01-26 Treatment with anti-TIGIT antibody and PD-1 axis binding antagonist

Country Status (12)

Country Link
US (1) US20210395366A1 (en)
EP (1) EP4168118A1 (en)
JP (1) JP2023531200A (en)
KR (1) KR20230024368A (en)
CN (1) CN115916348A (en)
AU (1) AU2021293507A1 (en)
BR (1) BR112022025801A2 (en)
CA (1) CA3181672A1 (en)
IL (1) IL298946A (en)
MX (1) MX2022015881A (en)
TW (1) TW202200616A (en)
WO (1) WO2021257124A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689909A4 (en) * 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment
WO2024083074A1 (en) * 2022-10-17 2024-04-25 Beigene, Ltd. Formulations containing anti-tigit antibody and methods of use thereof

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Duke MODIFICATIONS OF THE STRUCTURE OF THE EGF RECEPTOR GENE IN HUMAN GLIOMA
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (en) 1993-12-24 2002-06-20 Merck Patent Gmbh immunoconjugates
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
RO121900B1 (en) 1996-04-12 2008-07-30 Warner-Lambert Company Irreversible inhibitors of tyrosine kinazes, pharmaceutical composition containing the same and use thereof
AR007857A1 (en) 1996-07-13 1999-11-24 Glaxo Group Ltd HETERO-CYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS, THYROSINE KINASE, THEIR PREPARATION METHODS, INTERMEDIARY USE IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
PL340800A1 (en) 1997-11-06 2001-02-26 American Cyanamid Co Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (en) 1997-12-05 2012-01-30 Scripps Research Inst Humanization of murine antibody
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 Method for regulating transcription of foreign genes
JP4668498B2 (en) 1999-10-19 2011-04-13 協和発酵キリン株式会社 Method for producing polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (en) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 Produce the cell of antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1478494B1 (en) 2002-02-26 2005-10-12 Advanced Micro Devices, Inc. Method and system for controlling the chemical mechanical polishing of substrates by calculating an overpolishing time and/or a polishing time of a final polishing step
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
JPWO2003084569A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Antibody composition-containing medicine
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
CN102911987B (en) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 The adorned cell of genome
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
ATE493433T1 (en) 2002-09-11 2011-01-15 Genentech Inc NEW COMPOSITION AND METHOD FOR TREATING IMMUNE DISEASES
US20060199181A1 (en) 2002-09-11 2006-09-07 Genentch, Inc. Compositions and methods for the treatment of immune related diseases
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0316779B1 (en) 2002-12-16 2020-04-28 Genentech Inc humanized antibody that binds human cd20, composition, manufactured article, apoptosis induction method, cd20 positive cancer treatment method, autoimmune disease treatment methods, isolated nucleic acids, expression vectors, host cells, method for producing a humanized 2h7 antibody, isolated polypeptide, liquid formulation, method of treating rheumatoid arthritis (ra) and humanized cd20 binding antibodies
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
RS58420B1 (en) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US8219149B2 (en) 2005-06-29 2012-07-10 Nokia Corporation Mobile communication terminal
SI1907424T1 (en) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CN108997498A (en) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
JP2012520314A (en) * 2009-03-11 2012-09-06 アムビト ビオスシエンセス コルポラチオン Combination of indazolylaminopyrrolotriazine and taxane for cancer treatment
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
MX354359B (en) 2011-03-29 2018-02-28 Roche Glycart Ag Antibody fc variants.
MY183503A (en) 2013-07-16 2021-02-23 Genentech Inc Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
EP3119913B1 (en) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
CN107073108A (en) 2014-07-16 2017-08-18 豪夫迈·罗氏有限公司 Use TIGIT inhibitor and the method for anti-cancer agent therapy cancer
UA122395C2 (en) 2014-08-19 2020-11-10 Мерк Шарп Енд Доум Корп. ANTIBODY AGAINST TIGIT
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
JO3620B1 (en) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
JP6976241B2 (en) 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Anti-TIGIT antibody
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
JP6764474B2 (en) 2015-09-25 2020-09-30 ジェネンテック， インコーポレイテッド Anti-TIGIT antibody and usage
UA125898C2 (en) 2016-03-04 2022-07-06 Джн Байосайєнсіз, Ллк Antibodies to tigit
EA201892362A1 (en) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
DK3455257T3 (en) 2016-05-09 2021-11-01 Igm Biosciences Inc ANTI-PD-L1 ANTIBODIES
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
PT3347379T (en) 2016-08-17 2020-02-18 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018047139A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
CN110662552A (en) 2016-11-30 2020-01-07 昂科梅德制药有限公司 Methods of cancer treatment comprising TIGIT binding agents
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
PT3565844T (en) * 2017-01-09 2023-05-02 Tesaro Inc Methods of treating cancer with anti-pd-1 antibodies
BR112019017298A2 (en) 2017-02-27 2020-04-14 Shattuck Labs Inc chimeric proteins based on tigit and light
BR112019017550A2 (en) 2017-02-28 2020-04-14 Seattle Genetics Inc isolated antibody, pharmaceutical composition, bispecific antibody, antibody-drug conjugate, isolated polynucleotide, vector, host cell, methods of producing an antibody and treating a cancer in a subject, and, kit
JOP20190203A1 (en) 2017-03-30 2019-09-03 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
MA50957A (en) 2017-05-01 2020-10-14 Agenus Inc ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE
EP3618855A4 (en) 2017-05-02 2021-02-17 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR20200013241A (en) 2017-05-25 2020-02-06 브리스톨-마이어스 스큅 컴퍼니 Antibodies Containing Modified Heavy Chain Constant Regions
JP7348072B2 (en) 2017-06-01 2023-09-20 コンピュジェン リミテッド Triple combination antibody therapy
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa Anti-tigit antibodies
EP3664817A4 (en) 2017-08-07 2021-09-22 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides
EP3689909A4 (en) 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
CA3082383A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
CA3087060A1 (en) * 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
TWI816729B (en) 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 Anti-tigit antibodies and their use as therapeutics and diagnostics
EP3740508A4 (en) 2018-01-15 2022-03-23 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against tigit
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
JP7156607B2 (en) 2018-02-06 2022-10-19 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド Antibodies against T-cell immunoreceptor (TIGIT) with IG and ITIM domains and uses thereof
CN111836831A (en) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 Administration for anti-TIGIT antagonist antibody and anti-PD-L1 antagonist antibody treatment
MX2020008795A (en) 2018-02-28 2020-10-08 Yuhan Corp Anti-tigit antibodies and uses thereof.
US20210379024A1 (en) 2018-03-14 2021-12-09 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
TW202015726A (en) * 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
SG11202011461TA (en) 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
SG11202100746WA (en) 2018-07-25 2021-03-30 Innovent Biologics Suzhou Co Ltd Anti-tigit antibody and use thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
WO2020047329A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
CN109384846B (en) * 2018-09-25 2020-03-03 合肥瑞达免疫药物研究所有限公司 Antibody capable of binding TIGIT (tungsten inert gas) or antigen-binding fragment thereof and application
EP3877418A4 (en) * 2018-11-05 2022-08-17 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
WO2020111018A1 (en) * 2018-11-27 2020-06-04 小野薬品工業株式会社 Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
CN113747947A (en) 2019-02-28 2021-12-03 沙塔克实验室有限公司 Combination therapy
CN109734806B (en) 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 Fully human anti-huTIGIT monoclonal antibody and application thereof
CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use
WO2021194481A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies

Similar Documents

Publication Publication Date Title
JP2020099324A5 (en)
JP2017533912A5 (en)
JP2017501167A5 (en)
JP2018508512A5 (en)
JP2017537090A5 (en)
JP2018518454A5 (en)
JP2019515008A5 (en)
JP2018538274A5 (en)
JP2018508483A5 (en)
IL294800A (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
RU2017133273A (en) PD-1 / PD-L1 INHIBITORS FOR CANCER TREATMENT
TW202233239A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
KR20200020902A (en) Immune treatment for hepatocellular carcinoma (HCC)
JP2013520442A5 (en)
JP2020527332A5 (en)
JP2020515577A5 (en)
JPWO2019165434A5 (en)
CN108079292A (en) A kind of purposes of anti-PD-1 antibody in the drug for preparing treatment liver cancer
JP2019524820A5 (en)
JP2019534251A5 (en)
CN109152838A (en) For the pyridine aldoxime methyliodide (PAM) monoclonal antibody for the treatment of cancer and the combination of Bo Maxini
CN109806393A (en) The purposes of anti-PD-1 antibody, pemetrexed and platinum medicine combination therapy non-small cell lung cancer
JP2024016209A5 (en)
JPWO2021257124A5 (en)
JPWO2021154761A5 (en)